Atreca, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCEL research report →
About the company
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform.
- CEO
- John A. Orwin
- IPO
- 2019
- Employees
- 90
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $3.57M
- P/E
- -0.04
- P/S
- 4.63
- P/B
- 0.04
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
- Gross Margin
- -819.61%
- Op Margin
- -12665.58%
- Net Margin
- -12617.79%
- ROE
- -83.28%
- ROIC
- -68.54%
- Revenue
- $770.00K · -9.52%
- Net Income
- $-97,157,000 · 11.13%
- EPS
- $-2.35 · 20.34%
- Op Income
- $-97,525,000
- FCF YoY
- 15.00%
- 52W High
- $1.20
- 52W Low
- $0.05
- 50D MA
- $0.09
- 200D MA
- $0.20
- Beta
- 1.03
- Avg Volume
- 267.00K
Get TickerSpark's AI analysis on BCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 11, 24 | Orwin John A | buy | 1 |
| Apr 1, 24 | Serafini Tito | sell | 20,788 |
| Sep 1, 23 | Orwin John A | sell | 22,951 |
| Sep 1, 23 | Serafini Tito | sell | 8,393 |
| Sep 1, 23 | Courtney Phillips | sell | 7,061 |
| Oct 19, 23 | BAKER BROS. ADVISORS LP | sell | 251,902 |
| Oct 19, 23 | BAKER BROS. ADVISORS LP | sell | 22,837 |
| Sep 17, 23 | Ruiz Roger Richard | other | 0 |
| Sep 17, 23 | Ruiz Roger Richard | other | 25,000 |
| Sep 17, 23 | Ruiz Roger Richard | other | 50,000 |
Our BCEL coverage
Recent articles, reports, and earnings notes.
No research on BCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCEL report →Similar companies
Peers in the same neighborhood.